---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-001784"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2024-01-19T23:59:59+00:00"
generated_at: "2026-06-06T20:58:16.680474+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sangamo Therapeutics eliminates 2023 executive bonuses, adopts retention program amid capital raise

## Summary
- Board determined not to award 2023 annual cash bonus to CEO Sandy Macrae or CFO Prathyusha Duraibabu.
- Retention program approved for US/UK employees; CEO eligible for up to $429,820, CFO up to $193,584.
- Retention payments conditioned on achieving capital-raising milestones by end of 2024 or change of control.
- Executives must remain employed through payment date; program highlights company's cash needs.

## SEC filing metadata
- accession: 0001628280-24-001784
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2024-01-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828024001784/0001628280-24-001784-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828024001784/sgmo-20240119.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-001784
- JSON: https://secwatch.observer/filing/0001628280-24-001784.json
- Plain text: https://secwatch.observer/filing/0001628280-24-001784.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.